Houston, TX – May 29, 2015 – BreviTest Technologies, developers of a next generation diagnostic testing platform that provides results at the point of care faster and more cost effectively, today announced the company was awarded $15,000 yesterday at the inaugural Texas New Ventures Competition presented by Texas A&M University System and the Research Valley Partnership.
BreviTest was chosen as one of 19 Texas-based companies to compete for top prize out of 91 eligible entries. Fannin Innovation Studio Entrepreneurship Fellow Erol Bakkalbasi, said, “Imagine the global impact in detecting Ebola in the field in under ten minutes and for less than $10. We’re turning the ELISA wet lab process on its head by making testing easier, faster and with results on par with those from a clinical lab.”
Unlike testing in clinical laboratories, which can take several hours and requires expensive equipment and experienced technicians, BreviTest’s technology can perform tests at the point of care in five to ten minutes, about the time it takes to brew a pot of coffee. Using customizable disposable cartridges and established chemistries, the technology could be used to perform a broad range of tests in the doctor’s office, emergency and non-emergency settings, home monitoring of chronic diseases and for allergen detection.
BreviTest’s novel approach re-imagines the immunoassay method as serial reactions in connected microfluidic chambers, which eliminates the traditional requirement of multiple washes to comprehensively remove residual reactants. BreviTest’s patent-pending technology has been reduced to practice with a prototype that successfully demonstrated completely automated ELISA reactions.
BreviTest Technologies, LLC is managed by Fannin Innovation Studios (www.fannininnovation.com/), an early-stage life science development firm that provides seed capital, office space and management support to its roster of portfolio companies.
About BreviTest Technologies, LLC
Founded in 2013, BreviTest is an early stage life sciences company that has developed a biomedical assay platform technology to perform ELISAs in a microfluidic environment. The patent pending technology has been reduced to practice with a point-of-care device. Significant advantages over current options include ultra-portable form factor, one-step user operation, runtime of 5-10 minutes, low price points for device and tests, and disposable cartridges catering to a wide variety of tests on same platform, while maintaining standard-of-care sensitivity and specificity.
About Fannin Innovation Studio
Houston-based Fannin Innovation Studio is an early-stage life sciences development group focused exclusively on commercializing medical technologies. Fannin partners with life science innovators to co-found startup companies by providing a pooled management team, central office space and seed funding. To further bridge the commercialization gap, Fannin’s apprenticeship program provides aspiring entrepreneurs with hands-on development experience with its portfolio companies.
For more information, visit www.FanninInnovation.com or email email@example.com